A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.

Zefei Jiang, Hua Yang, Wuyun Su et al.|Journal of Clinical Oncology|2022

Cited by 36